Mechanisms of this effect may include AhR modulation by urolithin A. The favorable safety profile makes possible the long-term administration of urolithin A. In this regard, clinical studies of long-term therapy with urolithin A for both prevention and add-on therapy of cancer are promising. This evidence concerns the gene AHR and cancer.